More on Baxter's (BAX) Q2: Global sales rise 3% Y/Y reflecting 3% revenue growth in the U.S. and...

|About: Baxter International Inc (BAX)|By:, SA News Editor

More on Baxter's (BAX) Q2: Global sales rise 3% Y/Y reflecting 3% revenue growth in the U.S. and internationally. Bioscience revenues come in at $1.6B, up 5% Y/Y as the company says demand for Advate and FEIBA is strong. Medical products revenues manage a 1% Y/Y gain (2% ex-currency impact) driven by "gains in peritoneal dialysis patients." Q3 guidance: $1.18-1.21/ share before items on sales growth of 9-12%, a figure that includes the Gambro acquisition and accounts for FX effects. For the full year, management sees EPS of $4.62-4.70 on sales growth of 7-8%. (PR)